During the United Kingdom (UK) Chemicals Stakeholder Forum’s (UKCSF) July 20, 2023, meeting, UKCSF received updates from the Department for Environment, Food and Rural Affairs (Defra) and the Health and Safety Executive (HSE) on UK REACH. According to the UKCSF Chemicals policy and regulation update, Defra, along with Welsh and Scottish governments, worked with
UK Health and Safety Executive (HSE)
Registration Now Open for “Preparing a PFAS Game Plan in the U.S., the UK, and the EU” Webinar
10:00 a.m. – 11:00 a.m. (EDT)
4:00 p.m. – 5:00 p.m. (CEST)
REGISTER NOW
Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are attracting global legal, regulatory, commercial, and litigation attention as no other “emerging contaminant” has. Companies producing, processing, distributing, and/or using these substances must be aware of these global legal developments and take steps now to…
HSE Recommends Restricting Hazardous Substances in Tattoo and Permanent Makeup Inks
The Health and Safety Executive (HSE) announced on June 8, 2023, that it is recommending the restriction of hazardous substances in ink used for tattooing and permanent makeup (PMU) in Great Britain (GB). HSE states that the proposed restriction would target substances classified for carcinogenicity, mutagenicity, reproductive toxicity, skin sensitization, skin corrosion, and serious eye…
HSE Proposes to Include Substances in UK REACH Substance Evaluation Rolling Action Plan
The Health and Safety Executive (HSE) has proposed to include three substances in the rolling action plan (RAP) for 2023 to 2025. HSE states that it has “sought to complement rather than replicate evaluation work that has been or will be performed by other regulatory regimes” (such as via the European Union’s (EU) Registration…
HSE Publishes RMOA for PFAS
On April 4, 2023, the Health and Safety Executive (HSE) published a regulatory management options analysis (RMOA) for per- and polyfluoroalkyl substances (PFAS). The RMOA is a preliminary step used within the UK Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) framework. The RMOA collates, combines, and analyzes information on the nature and extent of…
UK Parliament Environmental Audit Committee Seeks Stakeholder Views on Implementation of UK REACH
The Environmental Audit Committee of the United Kingdom (UK) Parliament announced on November 1, 2022, that it is planning an oral evidence session later in 2022 to examine progress in implementing UK REACH, which governs the registration, evaluation, and authorization of chemical products in England, Scotland, and Wales. The Committee plans to take evidence from…
DEFRA Calls for Evidence on Amending UK REACH Authorization List
The Department for Environment, Food and Rural Affairs (Defra) has published two calls for evidence on amending Annex 14 of UK REACH to include the following substances:
In December 2021, the Health and Safety Executive (HSE) recommended which substances of very high concern (SVHC) are a priority…
Defra Publishes Rationale for UK REACH Work Programme Priorities in 2022/23
The Health and Safety Executive (HSE) recently published the UK REACH Work Programme 2022/23. The work programme sets out the activity that HSE, supported by the Environment Agency and other relevant agencies, will carry out to operate UK REACH. To complement the publication of the work programme, the Department for Environment, Food and Rural…
HSE Begins Public Consultations on First Restriction Dossiers under UK REACH
By Lynn L. Bergeson and Carla N. Hutton
The United Kingdom (UK) Health and Safety Executive (HSE) announced on May 6, 2022, the beginning of a six-month public consultation on restriction proposals on lead in ammunition and substances in tattoo inks and permanent make-up (PMU). According to its press release, HSE proposed the restriction…
HSE Produces a Final Opinion on the First New REACH Application for Authorization
The Health and Safety Executive (HSE) recommends that MeiraGTx UK II Limited receive a 12-year review period for its use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (4-tert-OPnEO). The applicant uses the substance as a manufacturing aid in the production of gene therapy products at its manufacturing facility in London, UK.
4-ter-OPnEO is known to have endocrine-disrupting properties…